October 20, 2017 08:27 AM EDT
People

Biotech bad boy Mar­tin Shkre­li is­n't get­ting his $5M in bail mon­ey back any­time soon

John Carroll

Editor & Founder

Mar­tin Shkre­li and his at­tor­ney Ben Braf­man JS­tone/Shut­ter­stock

Mar­tin Shkre­li may be spend­ing his days chill­ing in a fed­er­al prison …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times